Screener
SG&A at other companies
Other financials
Where this comes from
Reported directly by Organogenesis Holdings Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Organogenesis Holdings Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:15 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338049
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total revenue | 43,755 | 101,005 | 80,983 | 187,698 |
| Operating expenses: | ||||
| Cost of goods sold | 23,673 | 27,630 | 49,445 | 51,353 |
| Selling, general and administrative | 53,965 | 73,810 | 119,151 | 146,319 |
| Research and development | 18,297 | 10,395 | 33,458 | 21,035 |
| Fair value adjustment to assets held for sale | (1,188) | 1,746 | (1,188) | 8,313 |
| Total operating expenses | 94,747 | 113,581 | 200,866 | 227,020 |
| Loss from operations | (50,992) | (12,576) | (119,883) | (39,322) |
Item 1. Unaudited Condensed Consolidated Financial Statements.
FAQ
- What is Organogenesis Holdings Inc.'s SG&A?
- Organogenesis Holdings Inc. (ORGO) reported SG&A of $53.97M in Q2 2026.
- How has Organogenesis Holdings Inc.'s SG&A changed year-over-year?
- Organogenesis Holdings Inc.'s SG&A decreased by 26.9% year-over-year, from $73.81M to $53.97M.
- What is the long-term trend for Organogenesis Holdings Inc.'s SG&A?
- Over 4 years (2021 to 2025), Organogenesis Holdings Inc.'s SG&A has grown at a 6.9% compound annual growth rate (CAGR), from $250.2M to $326.24M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Organogenesis Holdings Inc.'s sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude